FBXO22 and lung cancer: To further clarify the clinical relevance of FBXO22, we conducted IHC staining of a lung adenocarcinoma microarray and found that 73.8% of the lung cancer tissues showed high expression of FBXO22, while 76.2% of the adjacent tissues showed low expression of FBXO22, and the difference was statistically significant (Fig. 1F).